transient visual loss in a hepatitis c patient treated with pegylated interferon alfa-2a and ribavirin
نویسندگان
چکیده
introduction patients with hepatitis c are commonly treated with combination of pegylated interferon alfa-2a and ribavirin. less than 1% of patients receiving this treatment experience very uncommon ophthalmological side effects such as optic neuropathy and vision disorder, which are usually subclinical, mild and reversible, not requiring the withdrawal of the treatment. retinopathy is the most commonly reported ocular side effect of interferon use, usually presenting with cotton wool spots and retinal hemorrhages. case presentation we represent a case of severe retinopathy and optic neuropathy in a patient with chronic hepatitis c genotype 3a infection, treated with the combination of peg-ifn alfa-2a (180 mkg once weekly) and ribavirin (1200 mg daily). bilateral visual loss of both eyes developed at 11th week of therapy and changes in retina and optic nerve were observed. fluorescein angiography and optical coherence tomography showed bilateral anterior ischemic optic neuropathy and macular edema. visual acuity improved 1 month and fundoscopic changes were no longer present 6 months after the urgent permanent discontinuation of peg-ifn treatment and the pulse steroid therapy followed by a 2 week course of oral prednisone. discussion in case of interferon-associated retinopathy discontinuation of the therapy and treatment with high dose steroids can be beneficial. the prognosis of interferon-associated opthalmological side effects remains uncertain: in some patients visual acuity improves, other continues with poor visual outcome. considering that, all patients should undergo ophthalmologic examination before treatment with interferon and their ophthalmological status should be monitored regularly while receiving this therapy.
منابع مشابه
Transient Visual Loss in a Hepatitis C Patient Treated With Pegylated Interferon Alfa-2a and Ribavirin
INTRODUCTION Patients with Hepatitis C are commonly treated with combination of Pegylated Interferon alfa-2a and Ribavirin. Less than 1% of patients receiving this treatment experience very uncommon ophthalmological side effects such as optic neuropathy and vision disorder, which are usually subclinical, mild and reversible, not requiring the withdrawal of the treatment. Retinopathy is the most...
متن کاملNephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C.
متن کامل
Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
BACKGROUND Chronic hepatitis C virus (HCV) infection is associated with liver dysfunction and hepatocellular carcinoma. In patients with normal kidney function, treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) frequently leads to eradication of HCV. Treatment in dialysis patients has long been controversial and until recently, the use of RBV was considered to be contra-indicate...
متن کاملSafety and Efficacy of Pegylated Interferon Alfa-2a for the Treatment of Hepatitis C in Patients with Major Thalassemia
Background: Hepatitis C virus (HCV) infection is the most common transfusion transmitted disease in poly-transfused patients worldwide. In this study we aimed to evaluate the effects of pegylated interferon alfa-2a (PEG-IFN A-2a) in reducing serum ALT and eradicating serum hepatitis C virus (HCV) RNA in HCV infected polytransfused thalassemic patients. Materials and Methods: A cohort of 51 HCV-...
متن کاملPegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.
Until HCV NS3/4A protease inhibitors become available at the end of 2011, the combination pegylated-interferon (PEG-IFN)-alfa and ribavirin (RBV) will remain the standard treatment for chronic hepatitis C patients. In some hepatitis C virus-infected patients, PEG-IFN plus RBV treatment against HCV should continue to be used because of side effects of new drugs such as anemia. Our Japanese exper...
متن کاملInterstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C
Alkan E, Akin M, Adanir H, Tuna Y. Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C. Euroasian J Hepato-Gastroenterol 2016;6(1):91-92.
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
hepatitis monthlyجلد ۱۴، شماره ۲، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023